HIV protease inhibitors (HPIs) in combination with other antiretrovirals (for example, reverse transcriptase inhibitors) play a pivotal role in the management of HIV-infected patients. The therapeutic effects of these drugs is dependent on their cellular accumulation, which is in part affected by the expression of ATP binding cassette family of drug efflux transporters, such as P-glycoprotein (P-gp), multidrug resistance-associated proteins (MRPs) and breast cancer resistance protein (BCRP) [1] [2] [3] . In addition, there are some known anionic and cationic transporters, such as human organic anion transporting polypeptide (hOATP) and human organic cation transporters (hOCTs), respectively, which mediate the influx/ elimination of many clinically important drugs and xenobiotics, and these have been shown to limit the
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accumulation of some HPIs [2, [4] [5] [6] . All these transporters are differentially expressed in the liver, kidney, circulating lymphocytes, brain, testes and intestinessites important in drug disposition, or which might act as sanctuary for the replicating virus and/or support viral replication. Clearly, low intracellular/plasma drug concentration or altered distribution within these sites could affect clinical outcome.
The transporters work in concert to control the bioavailability of clinically important drugs and endogenous compounds. Thus, together with the cytochrome P450 enzymes, these transporters are important determinants of drug-drug interactions, drug efficacy and toxicity [7] . Indeed, previous studies have shown the oral availability, brain, and fetal penetration of saquinavir (SQV) to be limited by P-gp [8, 9] . Similarly, the intracellular accumulations of a number of HPIs have been shown to be limited by P-gp, MRP1, MRP2 and BCRP [1, 2, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . There is ample evidence that some HPIs also induce and inhibit the expression of drug efflux transporters, such as P-gp, MRP1/2 and BCRP [12, 16, [20] [21] [22] [23] [24] [25] . However, the role of BCRP in the efflux of HPIs is equivocal [1, 3, [24] [25] [26] [27] ; there is evidence that BCRP induces resistance to nucleoside reverse transcriptase inhibitors [27] .
We have shown that the intracellular concentrations of HPIs are amenable to manipulation by coadministration with inhibitors of drug efflux transporters [1, 2, 13] . A potential use of such agents would be to enhance intestinal drug absorption and increase drug penetration to biologically important protective barriers, such as the blood-brain, blood-cerebrospinal fluid, maternal-fetal barriers, testes, and within circulating lymphocytes that might be impenetrable to these drugs. To this end, because ritonavir-mediated inhibition of cytochrome P450 (CYP3A4/CYP2D6) and possibly P-gp has been shown to increase exposure to coadministered HPIs, ritonavir (RTV)-boosted HPIs are a standard component of antiretroviral regimen [28] . Interestingly, we and others have recently shown that other HPIs, such as atazanavir (ATV), can pharmacoenhance the intracellular accumulation and area under the curve of coadministed HPIs [2, 29] . Published evidence to date suggests that ATV might be a substrate, or induces or inhibits P-gp, MRP and BCRP activities [2, 3, 23, 25, 30, 31] , but does not alter lymphocyte expression of P-gp, and MRP1 [3, 31] . The current study aims to characterize the determinants of the cellular transport and sequestration of [ 
Methods

Reagents
Cell culture
The cultured cells used in this study were CEM (a CD4 + T-cell line), VBL (P-gp overexpressing; selected using vinblastine) and E1000 (MRP-1 overexpressing; selected using epirubicin). The expression of these transporters has been previously validated in our laboratory [13] . The cells were maintained at 37°C, 5% CO 2 in RPMI-1640 media supplemented with 10% fetal bovine serum (FBS).
Isolation of PBMCs
PBMCs were isolated from blood buffy coats using Lymphoprep according to the manufacturer's instructions.
Octanol/saline partition coefficient
As the cellular association of a drug within target cells is a composite of active influx/efflux, passive diffusion and ion trapping, the lipophilicity of [ 3 H]-ATV was measured as described previously [6] to establish if simple physiochemical characteristics were major determinants of intracellular accumulation.
Transport of [
3 H]-ATV and the effects of specific inhibitors on transport in CEM and CEM VBL cells
Initial experiments examined the optimal concentrations of inhibitors for maximal inhibitory effects on Pgp, MRP and hOATP activity. Cells (CEM and its variant cells) were incubated in the absence or presence of varying concentrations of XR9576 (0.01-1 µM; P-gp/BCRP inhibitor [32] [33] [34] ), MK571, dipyridamole (1-100 µM; P-gp/MRP inhibitor [35, 36] ), frusemide (1-100 µM; MRP1/2 inhibitor [1], GF120918 (1-100 µM; P-gp/ BCRP inhibitor [13, 37] ), GPV031 (1-100 µM; P-gp inhibitor [38] ), probenecid (1-100 µM; MRP/hOATP [14, 39] and E-3-S (1-100 µM; hOATP/hOCTP inhibitor [6, 40] ) as described [1] .
In subsequent experiments, the transport and accumulation of [ 3 H]-ATV (20 nM) was measured by incubating the cells (2.5×10 6 cells/ml) in the absence and presence of fixed concentrations of inhibitors: tariquidar (1 µM), frusemide (50 µM), dipyridamole (50 µM), E-3-S (30 and 100 µM), probenecid (30 and 100 µM), GPV031 (30 and 100 µM) and GF120918 (50 µM). We also investigated the interaction of soy-derived phytoestrogens daidzein and genistein (at 1 and 5 mM) known to interact with P-gp, MRP, BCRP and hOATP [41] [42] [43] [44] [45] [46] [47] on the cellular accumulation ratio (CAR) of [ H]-ATV was also investigated in CEM and its variant cells. All experiments were carried out in RPMI-1640 media supplemented with 10% FBS as described previously [1] . The amount of drug associated with the cells was quantified by taking a ratio of the amount of drug in the cell pellets to the amount of drug in a similar volume of the bathing media after incubation, taking cell volume (1 pl) into consideration. This ratio was defined as the CAR.
Accumulation of [ 3 H]-ATV in isolated PBMCs and the effects of modulators of accumulation
The assay was carried out essentially as described above. Briefly, isolated PBMCs (5×10 6 cells/ml; cell volume 0.4 pl) were incubated in the absence or presence of fixed concentrations of the inhibitors: tariquidar (1 µM), GF120918 (50 µM), frusemide (50 µM), dipyridamole (50 µM), GPV031 (30 and 100 µM), E-3-S (30 and 100 µM), and APV, IDV, LPV, NFV, RTV, SQV and TPV (all at 10 and 30 µM). In addition, we investigated the interaction of daidzein and genistein (1 and 5 mM, respectively) on the CAR of [ 
Effects of digitonin permeabilization on the transport of [ 3 H]-ATV
In order to characterize the energy dependence and accumulation of [ 3 H]-ATV, drug transport assays were carried out in cells pretreated without or with 20 µM digitonin as described previously [48] followed by steady-state drug accumulation assay. Cells were incubated with 20 µM digitonin prior to the addition of [ 
Effects of ATV on daunomycin accumulation and efflux in cultured cells
Daunomycin is a substrate of P-gp and its accumulation and efflux were performed as described previously [38] . Concentration-response curves were fitted to the data points using non-linear least-squares and 50% effective concentration values were calculated as described previously [38] .
Statistical analyses
Data are expressed as mean ±sd and the distribution of data was assessed using the Shapiro-Wilk test. Statistically significant differences between controls and drugtreated samples were further assessed using the MannWhitney U test of the StatsDirect statistical software (version 2.6.3; Cheshire, UK). Differences between means were considered to be significant for P<0.05.
Results
Octanol/saline partition coefficient
The octanol/saline partition coefficient for [ 
accumulation studies or subsequent to the accumulation studies. We observed that permeabilization of CEM and E1000 cells with digitonin significantly (P<0.05) reduced the accumulation of [ 3 H]-ATV in these cells by 47% and 30%, respectively. Unexpectedly, permeabilization of VBL cells with digitonin caused a significant (P<0.01) increase in accumulation (from 7.0 ±0.6 to 15.9 ±2.6; Figure 1A ). Identical results were obtained in experiments in which the effect of digitonin was assessed subsequent to the accumulation studies (data not shown). 
Effects of various
Transport of [ 3 H]-ATV in PBMCs and the effects of drug efflux inhibitors and HPIs on accumulation
We observed variable accumulation of [ 3 H]-ATV in the PBMCs ranging from 13.6 ±1.5 to 24.9 ±1.9. We previously showed that PBMCs express P-gp, MRP, BCRP and hOATP [1, 6] . Dipyridamole, E-3-S and GPV031 caused a modest decrease in accumulation ( Figure 1C) 
Atazanavir increases the accumulation and decreases the efflux of daunomycin in the cultured cells
ATV increased the accumulation and decreased the efflux of daunomycin in a concentration-dependent manner, with a 50% inhibitory concentration of 9.8 µM and 8.5 µM, respectively (Figure 3 ). However, ATV had no effects on the accumulation and efflux of daunomycin in the CEM line (data not shown). ]-mannitol (our positive control) was similar to that reported previously [49] .
Drug transporters are important determinants of variable drug accumulation, drug-drug interactions, efficacy, resistance and toxicity. There is ample evidence that some HPIs are substrates, inhibitors and inducers of drug transporters such as P-gp, MRP1/2, BCRP and hOATP/hOCTP [1, 2, 4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 50] . However, the role of drug transporters in the accumulation of ATV has not been well documented [2, 3, 25, 30, 31] . In order to characterize the transport profile of ATV, we studied its accumulation in cultured cells and in primary human cells, with known transporter expression profiles [1, 13] . These data provide evidence that ATV is a substrate of P-gp, and MRP1. This stems from the observations that there was differential accumulation of [ Figure 1A ) was unexpected ( Figure 1A and 1C) . Although we found no direct evidence that the influx of HPIs are sensitive to these drugs, and given that none of the drugs (at the concentrations and incubation times employed) are cytotoxic to the cells (data not shown), we postulate that the observed effects might be the result of inhibition of influx, competition for accumulation, or displacement of [ [52, 53] . Given that E-3-S, a substrate/inhibitor of hOATP/hOCT [4, 54] , significantly decreased the accumulation of [ [55] , it could also be possible that the effects of tariquidar on some of the cells might be the result of inhibition of an influx transporter not described elsewhere. As with the cultured CEM and its variant cells, the effects of inhibitors of drug transport proteins on the intracellular accumulation of drugs in PBMCs might depend on the relative expression of the transporters. We recently showed the expression of several drug efflux transporters on PBMCs and demonstrated that the accumulation of HPIs is amenable to modulation by inhibitors of drug efflux and influx transporters [1, 2, 6] . Here, inhibitors of drug efflux transporters, such as tariquidar, dipyridamole, frusemide and E-3-S, produced contrasting results to that measured for SQV and LPV [1, 2] . The following possibilities might explain these observations: reduced cell surface expression of the efflux and influx transporters; important drug-drug interactions; the transporter profile of ATV differs from other HPIs -ATV is acid-sensitive to absorption, inhibits hepatic uridine 5′-diphospho-glucuronosyltransferase and induces CYPs [56, 57] ; and identification of some additional properties of some of the inhibitors used, such as frusemide and dipyridamole, might have potential to inhibit drug uptake transporters. Clearly, the decrease in the accumulation of [ Soy-derived phytoestrogens, such as daidzein and genistein, have been reported to interact with some major drug transporters, including P-gp, MRP, BCRP and hOATP [42] [43] [44] [45] [46] [47] 58] . However, their interactions with HPIs are largely undefined. We observed that daidzein had dual effects, with the agents causing modest but significant decrease (at 1 mM) and increase (at 5 mM) in accumulation of [ [45] . Furthermore, it has also been shown that genistein induces the depolarization of membrane potential [59] , which might ultimately prevent the cellular accumulation of [ 3 H]-ATV. As serum concentrations of phytoestrogens could be high [60] , these data suggest that intake of soy tablets and or diets rich in soy might influence the accumulation, efficacy and toxicity of ATV. Taken together, these data suggest that these phytoestrogens are both inhibitors of influx and efflux transporters and that ATV might be a substrate of transporters that are affected by these phytoestrogens [42] [43] [44] [45] [46] [47] 58] .
The evidence that E-3-S significantly decreased the accumulation of [ Figures 1C and 2) , contrary to the lack of effects of tariquidar and frusemide alone ( Figures 1C and 2 (Figure 2 ). These observations indicate the potential for significant drug-drug and drug-endogenous-substance interactions. We also observed that ATV enhances both P-gp-mediated accumulation and inhibits P-gp-mediated efflux of daunomycin in VBL cells (Figure 3 ). This is in some agreement with previous studies, which show that although ATV does not induce P-gp or MRP expression [31, 61] , it is an inhibitor of P-gp (and MRP [2, 23, 30] and is also able to increase the plasma concentration of coadministered HPIs [29] via blunting the activities of P-gp/MRP [2] and possibly cytochrome P450 enzymes [30] .
RTV and other HPIs, including ATV, have been shown to modulate the plasma and intracellular concentrations of other HPIs [2, 28, 29] Figure 1C ). There is evidence that some antiretrovirals, such as IDV, RTV, SQV and efavirenz, are potent inhibitors of uptake transporters (for example, hOATP1B1) or hOCTs [5, 62, 63] . Some of the HPIs (for example, APV, IDV and SQV) reduced the accumulation of ATV in the P-gp overexpressing VBL cells ( Figure 1B and 1C) . In a previous investigation, we observed that of the hOATP isoforms studied, only VBL cells express hOATP1A2 [6] . Given that some of these HPIs are also substrates of hOATP [6] , it is probably that the inhibitory effects of some of the HPIs on the accumulation of ATV are a direct result of their competition for entry into the cells with ATV. Overall, these observations plus that observed with probenecid suggest that ATV might be a substrate of uptake transporters. Thus its coadministration with some HPIs or probenecid might result in alterations in its cellular accumulation
Investigations that aim to characterize the role of drug transporters and the influence of drug embedding/ sequestering into cell membranes on the accumulation of [ that observed with the inhibitors alone, suggesting lack of interaction between the coadministered agents.
In conclusion, we found that ATV is lipophilic, is a substrate of P-gp, MRP and hOATPs and is an inhibitor of P-gp, making its disposition susceptible to alteration by coadministered drugs and dietary components that interact with these transporters.
